ArticleInternational immunopharmacology2022
Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19.
Article in International immunopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Nutritional and inflammatory biomarkers for COVID-19 susceptibility: a focus on vitamin D, potassium, and hematological indices.BMC infectious diseases · 2025Article
- The diagnostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in malaria: insights and implications - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Efficacy of monocyte distribution width in predicting critical illness in patients with COVID-19 pneumonia: a retrospective cohort study.BMC infectious diseases · 2025Article
- Review
- Predictive Value of Traditional and Novel Composite Inflammatory Indicators for Severe and Refractory Mycoplasma pneumoniae Pneumonia in Children.Journal of inflammation research · 2025Article
- C-reactive protein to lymphocyte ratio combined with clinical features to construct a predictive model for upper gastrointestinal bleeding due to peptic ulcer.Clinics (Sao Paulo, Brazil) · 2025Article
- Evaluation of the Efficacy of a Nomogram to Predict Multidrug-Resistant Pulmonary Infections Based on Data from Neurosurgery Ward Patients.Infection and drug resistance · 2025Article
- Notable correlation between serum epidermal growth factor values and inflammatory status in patients with COVID-19.Immunity, inflammation and disease · 2024Observational
- Article
- Evaluation of hematological changes and immune response biomarkers as a prognostic factor in critical patients with COVID-19.PloS one · 2024Article
- Predictive value of D-dimer to albumin ratio for severe illness and mortality in patients with COVID-19.Frontiers in medicine · 2024Article
- sTREM-1 as a Predictive Biomarker for Disease Severity and Prognosis in COVID-19 Patients.Journal of inflammation research · 2024Article
- [Early prediction of severe COVID-19 in patients with Sjögren's syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Article
- Serial Changes in Blood-Cell-Count-Derived and CRP-Derived Inflammatory Indices of COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Article
- [Hematological indices associated with mortality in critically ill patients with COVID-19].Revista medica del Instituto Mexicano del Seguro Social · 2023Observational
- Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR) - Risk of Death Inflammatory Biomarkers in Patients with COVID-19.Journal of inflammation research · 2023Article
- The neutrophil-lymphocyte ratio predicts all-cause and cardiovascular mortality among U.S. adults with rheumatoid arthritis: results from NHANES 1999-2020.Frontiers in immunology · 2023Article
- During the Omicron Pandemic Wave, the Severe Systemic Inflammatory Status of COVID-19 Indicated a Higher Risk of In-Hospital Mortality and Mediated the Clinical Efficacy of Corticosteroids.Infection and drug resistance · 2023Article
- C-Reactive Protein-to-Albumin Ratio (CAR) and C-Reactive Protein-to-Lymphocyte Ratio (CLR) are Valuable Inflammatory Biomarker Combination for the Accurate Prediction of Periprosthetic Joint Infection.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectThe study aimed to utilize the peripheral blood immunological parameters and resulting individual and combined inflammatory indices [neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR) and C-reactive protein/lymphocyte ratio (CLR)] in predicting the prognosis and mortality in COVID-19 patients. MATERIALS AND
methodsThe measurements of individual and combined inflammatory indices (NLR, LMR and CLR) were performed at hospital admission and at last day of hospitalization for COVID-19 patients.
resultsProminent elevation of NLR and CLR among patients with refractory disease admitted to Intensive Care Unit (ICU) and deceased patients was found when compared with moderate ill patients and healthy controls. Interestingly, NLR and CLR typically returned to near normal value as patients recover from severe infection. By contrast, deceased patients had persistent increased NLR and CLR until last day of hospitalization in ICU. ROC obtained for the above parameters showed that NLR and CLR were the most associated immunological parameters with the severity of COVID-19 disease. Using multivariate logistic regression analysis, CLR > 69.46 is an independent prognostic factors in identifying critically ill COVID-19 cases. Study of the combined markers NLR and CLR showed that most of patients admitted in ICU were characterized with high NLR combined with high CLR, while most of healthy subjects and non-ICU group have low NLR combined with low CLR.
conclusionThe combination of NLR and CLR could improve the predictive efficacy compared to individual markers to segregate patients who will develop a severe disease from those with a mild pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.